3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Sell
32
SAUHY Quote, Financials, Valuation and Earnings
Last price:
$12.57
Seasonality move
:
5.38%
Day range:
$12.30 - $12.95
52-week range:
$11.83 - $17.23
Dividend yield:
0.74%
P/E ratio:
68.66x
P/S ratio:
7.06x
P/B ratio:
9.15x
Volume:
140.5K
Avg. volume:
101.2K
1-year change:
-17.03%
Market cap:
$20B
Revenue:
$2.7B
EPS (TTM):
$0.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SAUHY
Straumann Holding AG
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$633.2K | -$0.22 | -96.14% | -284.28% | $10.25 |
|
ADXN
Addex Therapeutics
|
$177.2K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$7.8M | -$1.21 | -96.15% | -0.36% | $84.63 |
|
MOLN
Molecular Partners AG
|
-- | -$0.45 | -100% | -33.3% | $10.51 |
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SAUHY
Straumann Holding AG
|
$12.57 | -- | $20B | 68.66x | $0.04 | 0.74% | 7.06x |
|
ACIU
AC Immune SA
|
$2.98 | $10.25 | $294.9M | -- | $0.00 | 0% | -- |
|
ADXN
Addex Therapeutics
|
$7.98 | $30.00 | $8.5M | -- | $0.00 | 0% | 14.74x |
|
CRSP
CRISPR Therapeutics AG
|
$42.43 | $84.63 | $3.6B | -- | $0.00 | 0% | -- |
|
MOLN
Molecular Partners AG
|
$5.06 | $10.51 | $186.2M | -- | $0.00 | 0% | 24.55x |
|
NLSP
NLS Pharmaceutics
|
$2.09 | -- | $8M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SAUHY
Straumann Holding AG
|
-- | 1.539 | -- | 1.31x |
|
ACIU
AC Immune SA
|
-- | 5.710 | -- | 1.82x |
|
ADXN
Addex Therapeutics
|
-- | 3.160 | -- | 4.36x |
|
CRSP
CRISPR Therapeutics AG
|
-- | 3.448 | -- | -- |
|
MOLN
Molecular Partners AG
|
-- | 2.282 | -- | 14.08x |
|
NLSP
NLS Pharmaceutics
|
-- | 2.905 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SAUHY
Straumann Holding AG
|
-- | -- | 13.38% | 13.88% | -- | -- |
|
ACIU
AC Immune SA
|
-- | $8.4M | -28.55% | -28.55% | 21.72% | -$12.8M |
|
ADXN
Addex Therapeutics
|
-- | -$719.5K | 91.08% | 91.08% | -2836.3% | -$713.3K |
|
CRSP
CRISPR Therapeutics AG
|
-$11.2M | -$110.1M | -- | -- | -- | -$107.1M |
|
MOLN
Molecular Partners AG
|
-- | -$16.9M | -37.36% | -37.36% | -2407.93% | -$17.3M |
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- | -- |
Straumann Holding AG vs. Competitors
-
Which has Higher Returns SAUHY or ACIU?
AC Immune SA has a net margin of -- compared to Straumann Holding AG's net margin of 21.59%. Straumann Holding AG's return on equity of 13.88% beat AC Immune SA's return on equity of -28.55%.
Company Gross Margin Earnings Per Share Invested Capital SAUHYStraumann Holding AG-- -- $2.2B ACIUAC Immune SA-- $0.06 $154.7M -
What do Analysts Say About SAUHY or ACIU?
Straumann Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $10.25 which suggests that it could grow by 243.81%. Given that AC Immune SA has higher upside potential than Straumann Holding AG, analysts believe AC Immune SA is more attractive than Straumann Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings SAUHYStraumann Holding AG0 0 0 ACIUAC Immune SA3 0 0 -
Is SAUHY or ACIU More Risky?
Straumann Holding AG has a beta of 1.450, which suggesting that the stock is 44.952% more volatile than S&P 500. In comparison AC Immune SA has a beta of 1.294, suggesting its more volatile than the S&P 500 by 29.428%.
-
Which is a Better Dividend Stock SAUHY or ACIU?
Straumann Holding AG has a quarterly dividend of $0.04 per share corresponding to a yield of 0.74%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Straumann Holding AG pays 51.79% of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend. Straumann Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SAUHY or ACIU?
Straumann Holding AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $29.5M. Straumann Holding AG's net income of -- is lower than AC Immune SA's net income of $6.4M. Notably, Straumann Holding AG's price-to-earnings ratio is 68.66x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Straumann Holding AG is 7.06x versus -- for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAUHYStraumann Holding AG7.06x 68.66x -- -- ACIUAC Immune SA-- -- $29.5M $6.4M
-
Which has Higher Returns SAUHY or ADXN?
Addex Therapeutics has a net margin of -- compared to Straumann Holding AG's net margin of -2841.85%. Straumann Holding AG's return on equity of 13.88% beat Addex Therapeutics's return on equity of 91.08%.
Company Gross Margin Earnings Per Share Invested Capital SAUHYStraumann Holding AG-- -- $2.2B ADXNAddex Therapeutics-- -$2.78 $13.1M -
What do Analysts Say About SAUHY or ADXN?
Straumann Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 275.94%. Given that Addex Therapeutics has higher upside potential than Straumann Holding AG, analysts believe Addex Therapeutics is more attractive than Straumann Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings SAUHYStraumann Holding AG0 0 0 ADXNAddex Therapeutics0 0 0 -
Is SAUHY or ADXN More Risky?
Straumann Holding AG has a beta of 1.450, which suggesting that the stock is 44.952% more volatile than S&P 500. In comparison Addex Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SAUHY or ADXN?
Straumann Holding AG has a quarterly dividend of $0.04 per share corresponding to a yield of 0.74%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Straumann Holding AG pays 51.79% of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend. Straumann Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SAUHY or ADXN?
Straumann Holding AG quarterly revenues are --, which are smaller than Addex Therapeutics quarterly revenues of $62.3K. Straumann Holding AG's net income of -- is lower than Addex Therapeutics's net income of -$1.8M. Notably, Straumann Holding AG's price-to-earnings ratio is 68.66x while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Straumann Holding AG is 7.06x versus 14.74x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAUHYStraumann Holding AG7.06x 68.66x -- -- ADXNAddex Therapeutics14.74x -- $62.3K -$1.8M
-
Which has Higher Returns SAUHY or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to Straumann Holding AG's net margin of --. Straumann Holding AG's return on equity of 13.88% beat CRISPR Therapeutics AG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SAUHYStraumann Holding AG-- -- $2.2B CRSPCRISPR Therapeutics AG-- -$1.01 -- -
What do Analysts Say About SAUHY or CRSP?
Straumann Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $84.63 which suggests that it could grow by 99.45%. Given that CRISPR Therapeutics AG has higher upside potential than Straumann Holding AG, analysts believe CRISPR Therapeutics AG is more attractive than Straumann Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings SAUHYStraumann Holding AG0 0 0 CRSPCRISPR Therapeutics AG11 11 2 -
Is SAUHY or CRSP More Risky?
Straumann Holding AG has a beta of 1.450, which suggesting that the stock is 44.952% more volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.681, suggesting its more volatile than the S&P 500 by 68.115%.
-
Which is a Better Dividend Stock SAUHY or CRSP?
Straumann Holding AG has a quarterly dividend of $0.04 per share corresponding to a yield of 0.74%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Straumann Holding AG pays 51.79% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Straumann Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SAUHY or CRSP?
Straumann Holding AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of --. Straumann Holding AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$85.9M. Notably, Straumann Holding AG's price-to-earnings ratio is 68.66x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Straumann Holding AG is 7.06x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAUHYStraumann Holding AG7.06x 68.66x -- -- CRSPCRISPR Therapeutics AG-- -- -- -$85.9M
-
Which has Higher Returns SAUHY or MOLN?
Molecular Partners AG has a net margin of -- compared to Straumann Holding AG's net margin of -2408.81%. Straumann Holding AG's return on equity of 13.88% beat Molecular Partners AG's return on equity of -37.36%.
Company Gross Margin Earnings Per Share Invested Capital SAUHYStraumann Holding AG-- -- $2.2B MOLNMolecular Partners AG-- -$0.57 $165M -
What do Analysts Say About SAUHY or MOLN?
Straumann Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Molecular Partners AG has an analysts' consensus of $10.51 which suggests that it could grow by 107.99%. Given that Molecular Partners AG has higher upside potential than Straumann Holding AG, analysts believe Molecular Partners AG is more attractive than Straumann Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings SAUHYStraumann Holding AG0 0 0 MOLNMolecular Partners AG2 1 0 -
Is SAUHY or MOLN More Risky?
Straumann Holding AG has a beta of 1.450, which suggesting that the stock is 44.952% more volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SAUHY or MOLN?
Straumann Holding AG has a quarterly dividend of $0.04 per share corresponding to a yield of 0.74%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Straumann Holding AG pays 51.79% of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend. Straumann Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SAUHY or MOLN?
Straumann Holding AG quarterly revenues are --, which are smaller than Molecular Partners AG quarterly revenues of $787.5K. Straumann Holding AG's net income of -- is lower than Molecular Partners AG's net income of -$19M. Notably, Straumann Holding AG's price-to-earnings ratio is 68.66x while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Straumann Holding AG is 7.06x versus 24.55x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAUHYStraumann Holding AG7.06x 68.66x -- -- MOLNMolecular Partners AG24.55x -- $787.5K -$19M
-
Which has Higher Returns SAUHY or NLSP?
NLS Pharmaceutics has a net margin of -- compared to Straumann Holding AG's net margin of --. Straumann Holding AG's return on equity of 13.88% beat NLS Pharmaceutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SAUHYStraumann Holding AG-- -- $2.2B NLSPNLS Pharmaceutics-- -- -- -
What do Analysts Say About SAUHY or NLSP?
Straumann Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 11383.25%. Given that NLS Pharmaceutics has higher upside potential than Straumann Holding AG, analysts believe NLS Pharmaceutics is more attractive than Straumann Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings SAUHYStraumann Holding AG0 0 0 NLSPNLS Pharmaceutics0 0 0 -
Is SAUHY or NLSP More Risky?
Straumann Holding AG has a beta of 1.450, which suggesting that the stock is 44.952% more volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SAUHY or NLSP?
Straumann Holding AG has a quarterly dividend of $0.04 per share corresponding to a yield of 0.74%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Straumann Holding AG pays 51.79% of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend. Straumann Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SAUHY or NLSP?
Straumann Holding AG quarterly revenues are --, which are smaller than NLS Pharmaceutics quarterly revenues of --. Straumann Holding AG's net income of -- is lower than NLS Pharmaceutics's net income of --. Notably, Straumann Holding AG's price-to-earnings ratio is 68.66x while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Straumann Holding AG is 7.06x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAUHYStraumann Holding AG7.06x 68.66x -- -- NLSPNLS Pharmaceutics-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 30.64% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is up 22.41% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is up 18.99% over the past day.
